MedPath

To evaluate the safety and efficacy of orally administered supplement SJ29 Capsule in sickle cell anemia patients

Phase 3
Conditions
Health Condition 1: D571- Sickle-cell disease without crisis
Registration Number
CTRI/2024/07/070723
Lead Sponsor
Athulya Ayurvedic Medical Research Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Male or female over 18 to 30 years, both inclusive.

2. non smokers.

3. BMI greater than 18 kg/m2.

4. Patients diagnosed with sickle cell disease (documented by hemoglobin electrophoresis) and carrying SS or Sbeta0 version of the beta globin gene (documented by genotyping, known through medical history).

5. Hemoglobin levels between 5.5 and 10.5 g/dl during screening (for newly diagnosed or patients not on any treatment for SCD).

6. If the patient has been treated with an anti-sickling agent within three months with the intent to continue for the duration of the study.

7. Available to attend on an outpatient basis for visits provided for in the protocol and able to complete the data collection documents (compliance and quality of life scale)

8. Patient or the patients legally authorized representative has given written informed consent.

9. Able and willing to follow all study related instructions.

10. Must be willing to give written informed consent and comply with the study procedures.

Exclusion Criteria

1.Females who are pregnant or breastfeeding.

2.Patient has a significant medical condition that required hospitalization (other than sickle cell crisis) within two months of the screening visit.

3.Patient with diagnosed cancer in the past 2 years.

4.Patients participating simultaneously in another clinical research protocol or having recently participated in another research for which the exclusion period has not been completed.

5.Majors under legal protection or unable to express their consent.

6.People in an emergency situation unable to express their prior consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath